Schilde and Richter Pharma parted ways a little over a year and a half ago, the company confirmed on Tuesday in response to an OÖN request. The logistics specialist, previously head of finance at Schachinger Logistik and Hödlmayr, joined Richter Pharma in April 2023 and was responsible for operational business.
At the time it was said that this was taking place against the background of a large investment program that Richter Pharma had announced. 100 million euros are to be invested within seven years.
In Schilde’s place, Petra Hofer will now join the board. She has been working for the company since 2020 and previously worked in the Finance & Controlling department. She is now responsible for the finances of the leading company and forms the management duo with the long-time CEO Roland Huemer.
Image: Richter Pharma
“}”>
Image: Richter Pharma
“Richter Pharma is a recognized leading company in the Austrian healthcare industry. Above all, the company is in a growth phase in which I can profitably use my expertise in the financial sector,” Hofer is quoted as saying in a press release. Huemer and Supervisory Board Chairman Florian Fritsch shower roses on the new CFO.
**Interview with Dr. Martin Schilde, Former COO of Richter Pharma**
**Interviewer:** Thank you for joining us, Dr. Schilde. Can you tell us briefly about your time at Richter Pharma and why you decided to part ways?
**Dr. Schilde:** Thank you for having me. My time at Richter Pharma was an invaluable experience. When I joined in April 2023, I was excited to be part of a significant investment program aimed at enhancing the company’s operational capabilities. However, after a year and a half, I recognized that my vision for the operational strategies did not align as closely with the company’s direction, leading us to this mutual decision to part ways.
**Interviewer:** There was an announcement regarding a substantial investment program of 100 million euros over seven years. How do you see that impacting Richter Pharma’s future?
**Dr. Schilde:** The investment program is a crucial step for Richter Pharma. It presents an opportunity to innovate and expand our operational capabilities, which is vital in the competitive pharmaceutical landscape. I believe that with the right strategic implementation, it can significantly strengthen the company’s position in the market.
**Interviewer:** Petra Hofer has been appointed to succeed you on the board. What qualities do you think she brings to the role?
**Dr. Schilde:** Petra has a wealth of experience and has been with the company for some time. Her understanding of Richter Pharma’s operations and culture makes her an excellent choice for this position. I am confident that she will continue to drive the company’s objectives forward effectively.
**Interviewer:** What are your future plans now that you have left Richter Pharma?
**Dr. Schilde:** I am exploring opportunities that align more closely with my vision and expertise in operational strategy. I am open to new ventures that allow me to leverage my experience in the logistics and pharmaceutical sectors.
**Interviewer:** Thank you, Dr. Schilde, for sharing your insights. We wish you the best in your future initiatives.
**Dr. Schilde:** Thank you. I appreciate the opportunity to discuss my experiences.
